Distalmotion secures $150 Million to expand robotic surgery system in US
Share this article
The Biopôle-based company (Vaud) developed the DEXTER® Robotic Surgery System, a soft tissue surgical robot that uniquely simplifies operations to make the benefits of wristed robotics accessible in any operating room (OR).
This new funding will be used primarily to accelerate US commercial adoption of DEXTER, its soft tissue robotic surgery system, as well as to support ongoing clinical and product development initiatives. A major focus of the US expansion continues to be the Ambulatory Surgery Center (ASC) market—one of the fastest-growing segments in surgical care, driven by the ongoing shift toward efficient, outpatient surgery.
“This funding marks another important milestone on our journey,” said Greg Roche, CEO of Distalmotion. “The continued commitment of our investors validates our vision to break down barriers to robotic access through simplified operations. As we enter our next phase of US market acceleration, ASCs represent a tremendous opportunity for DEXTER. The ongoing support from our investors reaffirms our roadmap, our mission, and the value DEXTER brings to minimally invasive surgery.”
In conjunction with the financing, Distalmotion has named Chas McKhann as Executive Chairman of the Board of Directors. Mr. McKhann previously served as CEO of Apollo Endosurgery and then Silk Road Medical, and has more then 25 years of experience in the MedTech and life sciences industries.
DEXTER has been successfully integrated into clinical practice across Europe and the US, with almost 3,000 patients treated. With strong clinical traction and continued investment, Distalmotion is positioned to empower more surgeons across sites of care to deliver the benefits of robotic surgery to their patients.
➡️ Source: Press Release | 📸 ©Distalmotion